Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

99 trials with published results (28%)

Research Maturity

234 completed trials (67% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

7.7%

27 terminated out of 351 trials

Success Rate

89.7%

+3.1% vs benchmark

Late-Stage Pipeline

28%

100 trials in Phase 3/4

Results Transparency

42%

99 of 234 completed with results

Key Signals

99 with results90% success27 terminated

Data Visualizations

Phase Distribution

301Total
Not Applicable (112)
Early P 1 (1)
P 1 (24)
P 2 (64)
P 3 (70)
P 4 (30)

Trial Status

Completed234
Recruiting33
Terminated27
Unknown27
Withdrawn11
Not Yet Recruiting8

Trial Success Rate

89.7%

Benchmark: 86.5%

Based on 234 completed trials

Clinical Trials (351)

Showing 20 of 20 trials
NCT07573176Phase 3Not Yet RecruitingPrimary

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

NCT05915013Phase 1RecruitingPrimary

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

NCT04984512Phase 2RecruitingPrimary

The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder

NCT06860958Phase 3RecruitingPrimary

Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

NCT06982820Not ApplicableRecruitingPrimary

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

NCT04790630Not ApplicableCompleted

Cognitive Fitness for Depression in Older Adults

NCT02994433Phase 1RecruitingPrimary

NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

NCT06546917Not ApplicableRecruitingPrimary

bWell-D Pilot Randomized Controlled Trial

NCT03586427Phase 2CompletedPrimary

Zelquistinel in the Treatment of Major Depressive Disorder

NCT06308653Phase 3Active Not RecruitingPrimary

Psilocybin for Major Depressive Disorder (MDD)

NCT06254144CompletedPrimary

Neuroimaging Study for Decoding Emotional States and Identifying Neural Circuits to Disengage From Negative Thinking

NCT05841030CompletedPrimary

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

NCT07540585Not Yet Recruiting

MOCHA: Embedded Inpatient Mental Health Care for High-Risk Perinatal Patients

NCT03866174Phase 2CompletedPrimary

A Study of Psilocybin for Major Depressive Disorder (MDD)

NCT05306184Active Not RecruitingPrimary

Prospective Assessment of Cost-effectiveness and Side-effects of Depressive Patients Treated With ECT or TCA

NCT06913309Not ApplicableRecruitingPrimary

Clinical Efficacy, Safety, and Applicability of Home-based Bright Light Therapy in Outpatient Adolescents With Major Depressive Disorder

NCT06511908Phase 2Recruiting

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT05518149Phase 3TerminatedPrimary

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

NCT06934135Not ApplicableCompleted

Trial of Transcranial Photobiomodulation for Depression With PET and EEG Outcomes

NCT07258485RecruitingPrimary

A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)

Scroll to load more

Research Network

Activity Timeline